JP2013518882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518882A5 JP2013518882A5 JP2012551997A JP2012551997A JP2013518882A5 JP 2013518882 A5 JP2013518882 A5 JP 2013518882A5 JP 2012551997 A JP2012551997 A JP 2012551997A JP 2012551997 A JP2012551997 A JP 2012551997A JP 2013518882 A5 JP2013518882 A5 JP 2013518882A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- medicament
- day
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CN(C1NCN=C2NC=CC12)[C@@](C1)C(*)CCN1C(N*)=O Chemical compound CN(C1NCN=C2NC=CC12)[C@@](C1)C(*)CCN1C(N*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30191510P | 2010-02-05 | 2010-02-05 | |
| US61/301,915 | 2010-02-05 | ||
| PCT/US2011/022216 WO2011097087A1 (en) | 2010-02-05 | 2011-01-24 | Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013518882A JP2013518882A (ja) | 2013-05-23 |
| JP2013518882A5 true JP2013518882A5 (https=) | 2014-03-13 |
Family
ID=43629121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551997A Withdrawn JP2013518882A (ja) | 2010-02-05 | 2011-01-24 | ＪＡＫ阻害剤としてのピロロ［２，３−ｄ］ピリミジン尿素化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120309776A1 (https=) |
| EP (1) | EP2531508A1 (https=) |
| JP (1) | JP2013518882A (https=) |
| CN (1) | CN102822177A (https=) |
| AU (1) | AU2011213198B2 (https=) |
| BR (1) | BR112012019511A2 (https=) |
| CA (1) | CA2788071A1 (https=) |
| MX (1) | MX2012009074A (https=) |
| WO (1) | WO2011097087A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| JP2015528501A (ja) * | 2012-09-12 | 2015-09-28 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 白斑の治療法 |
| PH12020551186B1 (en) | 2012-11-15 | 2024-03-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| CN103896946B (zh) * | 2012-12-28 | 2018-04-03 | 浙江导明医药科技有限公司 | 用于预防及治疗多种自身免疫疾病的新化合物 |
| US20160123982A1 (en) | 2013-02-04 | 2016-05-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
| US20140343034A1 (en) * | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| PT3006445T (pt) * | 2013-06-07 | 2018-01-09 | Jiangsu Hengrui Medicine Co | Bissulfato de inibidor de janus quinase (jak) e método de preparação para o mesmo |
| SMT202000315T1 (it) | 2013-08-07 | 2020-07-08 | Incyte Corp | Forme di dosaggio a rilascio prolungato per un inibitore di jak1 |
| CN105732637B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
| RS60237B1 (sr) | 2015-11-24 | 2020-06-30 | Theravance Biopharma R&D Ip Llc | Prolekovi jak inhibitornih jedinjenja za lečenje gastorintestinalne inflamatorne bolesti |
| US10973913B2 (en) | 2016-02-16 | 2021-04-13 | Washington University | JAK inhibitors and uses thereof |
| CN110418796A (zh) | 2017-03-08 | 2019-11-05 | 施万生物制药研发Ip有限责任公司 | 托法替尼(tofacitinib)的葡萄糖苷酸前药 |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| EP3609903A1 (en) | 2017-05-23 | 2020-02-19 | Theravance Biopharma R&D IP, LLC | Thiocarbamate prodrugs of tofacitinib |
| PH12019502605A1 (en) | 2017-05-23 | 2020-10-26 | Theravance Biopharma R&D Ip Llc | Glucuronide prodrugs of janus kinase inhibitors |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3290666B2 (ja) * | 1995-06-07 | 2002-06-10 | ファイザー・インコーポレーテッド | 複素環式の縮合環ピリミジン誘導体 |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| SK286640B6 (sk) | 1998-06-19 | 2009-03-05 | Pfizer Products Inc. | Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva |
| DE60037345T2 (de) | 1999-12-10 | 2008-11-13 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-Verbindungen |
| ATE423120T1 (de) * | 2000-06-26 | 2009-03-15 | Pfizer Prod Inc | Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe |
| JP2004502664A (ja) * | 2000-06-30 | 2004-01-29 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病処置用化合物 |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| AU2003278529A1 (en) | 2002-11-21 | 2004-06-15 | Pfizer Products Inc. | 3-amino-piperidine derivatives and processes for their preparation |
| US7732237B2 (en) | 2005-06-27 | 2010-06-08 | The Regents Of The University Of California | Quantum dot based optoelectronic device and method of making same |
| EP1913000B1 (en) | 2005-07-29 | 2012-01-11 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis |
| WO2008029237A2 (en) * | 2006-09-05 | 2008-03-13 | Pfizer Products Inc. | Combination therapies for rheumatoid arthritis |
-
2011
- 2011-01-24 MX MX2012009074A patent/MX2012009074A/es unknown
- 2011-01-24 BR BR112012019511A patent/BR112012019511A2/pt not_active IP Right Cessation
- 2011-01-24 CA CA2788071A patent/CA2788071A1/en not_active Abandoned
- 2011-01-24 AU AU2011213198A patent/AU2011213198B2/en not_active Expired - Fee Related
- 2011-01-24 CN CN2011800171067A patent/CN102822177A/zh active Pending
- 2011-01-24 WO PCT/US2011/022216 patent/WO2011097087A1/en not_active Ceased
- 2011-01-24 JP JP2012551997A patent/JP2013518882A/ja not_active Withdrawn
- 2011-01-24 US US13/576,685 patent/US20120309776A1/en not_active Abandoned
- 2011-01-24 EP EP11703762A patent/EP2531508A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518882A5 (https=) | ||
| ES2910071T3 (es) | Compuestos de aminopirazina diol como inhibidores de PI3K-Y | |
| AU2011215638B2 (en) | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mGluR4 allosteric potentiators, compounds, and methods of treating neurological dysfunction | |
| JP7541594B2 (ja) | ＰＩ３Ｋ－γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体 | |
| KR20130079429A (ko) | 헤테로시클릭 설폰 mglur4 알로스테릭 강화제, 조성물 및 신경 기능이상을 치료하는 방법 | |
| KR20120120416A (ko) | Ｍｇｌｕｒ4 알로스테릭 강화제로서 벤즈이속사졸 및 아자벤즈이속사졸, 조성물, 및 신경 기능이상을 치료하는 방법 | |
| JP2013526544A5 (https=) | ||
| CL2011000353A1 (es) | Compuestos derivados de 1-{4-[metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino]ciclohexil}metanosulfonamida o una sal farmaceuticamente aceptable; forma cristalina de la sal maleato; procedimiento de preparacion; composicion farmaceutica; y uso para tratar enfermedades alergicas, cancer, lupus. | |
| JP2013514980A5 (https=) | ||
| KR20120129869A (ko) | Ｍｇｌｕｒ4 알로스테릭 강화제, 조성물 및 신경 기능이상을 치료하는 방법 | |
| JP2012514655A (ja) | フッ素含有化合物およびその使用法 | |
| JP2013510120A5 (https=) | ||
| JP2010077141A5 (https=) | ||
| JP2011006480A5 (https=) | ||
| KR20120115252A (ko) | Ｍｇｌｕｒ4 알로스테릭 강화제로서 아릴 및 헤테로아릴 설폰, 조성물 및 신경 기능이상을 치료하는 방법 | |
| JP2013522326A5 (https=) | ||
| JP2014500861A5 (https=) | ||
| JP2021519308A (ja) | 転写活性化タンパク質のイミダゾピペラジン阻害剤 | |
| JP2015509075A5 (https=) | ||
| JP2013518036A5 (https=) | ||
| JP2019529460A5 (https=) | ||
| JP2016513124A5 (https=) | ||
| JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
| SI2864328T1 (en) | Pharmaceutically active compounds | |
| JP2014515405A (ja) | オピオイド受容体アゴニストの逐次投与のための組成物 |